Showing results (91-100 of 127) with videos related to
Sort By:
Pageof 13
Journal of Dermatological Science|May 7, 2015
The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patientsYasuhiro Fujisawa, Koji Yoshino, Yoshio Kiyohara, et al.Journal of Cutaneous Pathology|January 19, 2008
A case of primary Epstein-Barr virus-associated cutaneous diffuse large B-cell lymphoma unassociated with iatrogenic or endogenous immune dysregulationYasutaka Tokuda, Mana Fukushima, Koh Nakazawa, et al.European Journal of Cancer (Oxford, England : 1990)|November 18, 2018
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II studyKenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, et al.Cancer Science|March 8, 2017
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanomaNaoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, et al.Japanese Journal of Clinical Oncology|October 24, 2008
A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomesKazuhiko Matsumoto, Hitomi Kubo, Hiroshi Murata, et al.Cancer Chemotherapy and Pharmacology|March 12, 2017
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, et al.Journal of Dermatological Science|June 23, 2016
A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumorsKuniaki Ohara, Yasuhiro Fujisawa, Koji Yoshino, et al.The Journal of Dermatology|March 26, 2024
Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanomaKenji Yokota, Tatsuya Takenouchi, Yasuhiro Fujisawa, et al.The Journal of Dermatology|October 23, 2019
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 studyKenji Yokota, Hiroshi Uchi, Hisashi Uhara, et al.The Journal of Investigative Dermatology|July 19, 2022
Functional Interplay between IL-9 and Peptide YY Contributes to Chronic Skin InflammationShiori Kamiya, Ippei Ikegami, Masahiro Yanagi, et al.Pageof 13